Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Puneet Singla

Psychiatry Grand Rapids, MI Medical Doctor

NPI 1558596429 CMS profile 24752

1055 Medical Park Dr Se, Grand Rapids, MI 49546

Open in the dashboard

General payments

$25,970

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Puneet Singla of Grand Rapids, MI is reported in the CMS Open Payments database as having received $25,970 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,075 57
2024 General $10,861 42
2023 General $450 9
2022 General $452 7
2021 General $593 6
2020 General $93 5
2019 General $447 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Puneet Singla
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Puneet Singla were reported at $13,075. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Puneet Singla Psychiatry median Middle half National median
2019 $447 $184 $59–$605 $163
2020 $93 $119 $36–$372 $114
2021 $593 $143 $43–$576 $132
2022 $452 $153 $50–$590 $149
2023 $450 $170 $56–$651 $160
2024 $10,861 $179 $57–$673 $164
2025 $13,075 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $23,070 84 payments
  2. Neurocrine Biosciences, Inc. $1,200 10 payments
  3. Janssen Pharmaceuticals, Inc $406 10 payments
  4. E.R. Squibb & Sons, L.L.C. $336 9 payments
  5. Otsuka America Pharmaceutical, Inc. $316 5 payments
  6. Axsome Therapeutics, Inc. $148 2 payments
  7. AbbVie, Inc. $134 2 payments
  8. Allergan Inc. $125 1 payment
  9. ITI, Inc. $84 3 payments
  10. Alkermes, Inc. $63 4 payments
  11. Other $89 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,480 10 payments
  2. Food and Beverage $4,233 112 payments
  3. Travel and Lodging $135 10 payments
  4. Education $123 2 payments
Products named General payments · program years 2019–2025
  1. UZEDY $22,923 80 payments
  2. INGREZZA Neuropsychiatry $587 5 payments
  3. INGREZZA Neurology $375 3 payments
  4. SPRAVATO $351 6 payments
  5. COBENFY $336 9 payments
  6. VRAYLAR $240 2 payments
  7. INGREZZA Neurology $238 2 payments
  8. ABILIFY MAINTENA $154 2 payments
  9. Auvelity $148 2 payments
  10. REXULTI $141 2 payments
  11. Other $642 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

249

Median for Psychiatry: 574

Drug cost

$3,733

Median for Psychiatry: $27,624

Branded share of claims

17.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Olanzapine Odt Olanzapine Brand 27 $1,589
Aripiprazole Generic 13 $363
Oxcarbazepine Generic 11 $287
Quetiapine Fumarate Generic 30 $252
Hydroxyzine Pamoate Generic 27 $231
Trazodone Hcl Generic 40 $231
Risperidone Generic 18 $228
Gabapentin Generic 16 $163
Olanzapine Generic 14 $124
Venlafaxine Hcl Er Venlafaxine Hcl Brand 16 $111

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$45,370

Medicare's payments for the services billed

Medicare patients

61

Average age 47

Services billed

668

27 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 49%
Diabetes 23%
Arthritis 23%
Atrial fibrillation 0%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
  • Teva Pharmaceuticals USA, Inc. $10,480
$10,480 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $269
$269 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record